KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Retained Earnings (2016 - 2025)

Nektar Therapeutics has reported Retained Earnings over the past 16 years, most recently at $17000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $17000.0 for Q4 2025, down 72.13% from a year ago — trailing twelve months through Dec 2025 was $17000.0 (down 72.13% YoY), and the annual figure for FY2025 was $17000.0, down 72.13%.
  • Retained Earnings for Q4 2025 was $17000.0 at Nektar Therapeutics, down from $56000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for NKTR hit a ceiling of $80000.0 in Q4 2023 and a floor of -$3.6 billion in Q3 2024.
  • Median Retained Earnings over the past 5 years was -$2.5 billion (2021), compared with a mean of -$1.7 billion.
  • Biggest five-year swings in Retained Earnings: plummeted 357812.45% in 2021 and later skyrocketed 100.0% in 2023.
  • Nektar Therapeutics' Retained Earnings stood at -$2.8 billion in 2021, then dropped by 13.0% to -$3.2 billion in 2022, then surged by 100.0% to $80000.0 in 2023, then dropped by 23.75% to $61000.0 in 2024, then plummeted by 72.13% to $17000.0 in 2025.
  • The last three reported values for Retained Earnings were $17000.0 (Q4 2025), $56000.0 (Q3 2025), and -$14000.0 (Q2 2025) per Business Quant data.